Samsung Bioepis secures Japan approval for its ustekinumab biosimilar with Nipro, marking a key step in Asia's biosimilar adoption. Find out what this means.
Kashiv BioSciences raises INR 648 crore to expand its Gujarat biologics facility. Find out what this means for India’s role in global drug manufacturing.
Zai Lab’s COBENFY approved in China as a first-in-class schizophrenia treatment. Find out what this milestone means for psychiatry and pharma innovation.
Coya Therapeutics expands its ALS trial for COYA 302 to Canada after Health Canada clearance. Explore what this means for the biotech’s immunotherapy platform.
Can Enveda’s ENV-6946 deliver the efficacy of biologics in a pill for IBD? Find out why its triple-cytokine Phase 1 trial is drawing industry attention.
Agenus sees 23% response rate in platinum-refractory ovarian cancer with BOT+BAL. Find out how this IO combo could reshape the treatment landscape.
Vyriad secures $85M to launch VV169, its in vivo CAR T therapy for multiple myeloma. Find out how this platform could reshape cancer immunotherapy.
Janux Therapeutics pushes JANX008 into Phase 1 expansion across EGFR+ cancers. Discover how masking technology may shift the immunotherapy safety paradigm.
Find out how Italfarmaco and JCR are bringing the DMD drug givinostat to Japan and what it means for rare disease innovation in Asia.
Gilead Sciences acquires Repare’s RP-3467 Polθ inhibitor for up to $30M. Find out what this means for BRCA-targeted therapy and synthetic lethality M&A.